Item 5.07 Submission of Matters to a Vote of Security Holders

At the Annual Meeting of Stockholders of Matinas BioPharma Holdings, Inc. (the "Company") held on November 1, 2021, our stockholders voted on the three proposals listed below. The proposals are described in detail in the Company's definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on September 17, 2021 (the "Proxy Statement"). The final results for the votes regarding each proposal are set forth below.





1. Our stockholders elected the following individuals to serve on our board of
directors until the annual meeting of shareholders to be held in 2022. The
tabulation of votes with respect to the election of such directors was as
follows:



                                    AUTHORITY        BROKER
                       FOR           WITHELD        NON-VOTE
Herbert Conrad       64,798,552      1,824,051      53,753,479

Jerome D. Jabbour    65,809,061        813,542      53,753,479

Kathryn Corzo        66,121,964        500,639      53,753,479

Eric Ende            65,348,649      1,273,954      53,753,479

Natasha Giordano     66,157,882        464,721      53,753,479

James Scibetta       65,356,479      1,266,124      53,753,479

Matthew Wikler       66,132,681        489,922      53,753,479

2. Our stockholders approved the ratification of the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2021. The tabulation of votes with respect to this proposal was as follows:





     For          Against      Abstain     Broker Non-Votes
  119,254,551      397,251      724,280

3. Our stockholders approved, on an advisory basis, the compensation of the Company's named executive officers. The tabulation of votes with respect to this proposal was as follows:





    For           Against       Abstain      Broker Non-Votes
  62,726,470      3,055,624      840,509            53,753,479

© Edgar Online, source Glimpses